| abstract |
The present invention provides an antibody modified to reduce the tendency to aggregate and a method for producing the same. The present invention also provides stable soluble scFv antibodies and Fab fragments specific for TNF, including specifically the light and heavy chain sequences optimized for stability, solubility, in vitro and in vivo binding of TNF, and immunogenicity. Nucleic acids, vectors and host cells for the expression of the recombinant antibodies of the invention, methods for their isolation and use of the antibodies in medicaments are also disclosed. |